Browsing Tag
IMCIVREE
3 posts
Is setmelanotide the first true disease-targeted therapy for hypothalamic obesity?
Is setmelanotide redefining hypothalamic obesity treatment? Explore what Rhythm Pharmaceuticals, Inc.’s EU approval means for markets and growth.
Rhythm Pharmaceuticals’ IMCIVREE hits regulatory speed bump as FDA extends decision timeline into 2026
Find out how Rhythm Pharmaceuticals’ IMCIVREE FDA review delay could shape the rare obesity treatment market in 2026.
Rhythm Pharmaceuticals (RYTM) surges 35% after announcing Phase 2 trial data reveal for oral MC4R agonist bivamelagon
Find out why Rhythm Pharmaceuticals stock surged over 35% and what the upcoming bivamelagon trial results mean for its rare disease pipeline.